Tags: Diagnostics Accelerator

announcements

Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia

The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd.  and Janssen Pharmaceuticals, Inc. as part of its  Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.

announcements

ADDF Clinical Trials Report Shows Notable Shift from Amyloid Approaches

The Alzheimer's Drug Discovery Foundation (ADDF) released a new clinical trial analysis report that shows researchers are now developing drugs for various targets associated with aging biology – moving beyond traditional amyloid and tau approaches.

announcements

Thirteenth Connoisseur's Dinner Recognizes Core Funders of Its Diagnostics Accelerator

The ADDF celebrated the one-year anniversary of the Diagnostics Accelerator initiative and its core funders at the ADDF's annual gala.

announcements

Alzheimer’s Drug Discovery Foundation Announces the First Diagnostics Accelerator Award Recipients

The first four awards from the first request for proposals total up to approximately $3.5 million.

announcements

The ADDF Announces New Research Initiative to Advance Digital Tools for Detection for Alzheimer's

The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.

announcements

ADDF Statement on Biogen and Eisai Discontinuing Trials of Aducanumab

Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.

blog

Top 5 Advances in 2018

In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.

announcements

The ADDF's Diagnostics Accelerator Initiative Expands Its Focus on Frontotemporal Degeneration

The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.

blog

Two Decades of Research: The ADDF's 19th International Conference on Alzheimer’s Drug Discovery

Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.

announcements

19th International Conference on Alzheimer's Drug Discovery Highlights Multiple Approaches

The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.